Spironolactone Therapy

FDA-Approved Indications

• The European Society of Cardiology recommends spironolactone in conjunction with other heart failure therapies, including ACE inhibitors and beta-blockers, for patients with heart failure with reduced ejection fraction 1
• The RALES trial demonstrated that spironolactone (25-50 mg daily) reduced mortality by 30% and heart failure hospitalizations by 35% when added to conventional therapy in patients with LVEF ≤35% 1
• The number needed to treat for 2 years to prevent one death is 9 in patients with severe heart failure 1
• Post-myocardial infarction patients with LVEF ≤40% and heart failure or diabetes also benefit from spironolactone, with a 15% reduction in mortality (EPHESUS trial with eplerenone) 1
• Spironolactone is the first-line diuretic for ascites in cirrhosis, with a 95% response rate compared to 52% for furosemide alone, as recommended by the European Association for the Study of the Liver 2
• The drug works by antagonizing secondary aldosteronism, which plays a major role in renal sodium retention in cirrhosis, according to the European Association for the Study of the Liver 2
• Target weight loss should not exceed 0.5 kg/day without peripheral edema, or 1 kg/day with peripheral edema, as suggested by the European Association for the Study of the Liver 2

Off-Label Uses with Evidence

• The American Academy of Ophthalmology notes that small prospective studies show potential benefit of spironolactone in central serous chorioretinopathy, with improved visual acuity, reduced choroidal thickness, and reduced subretinal fluid 3
• However, large randomized controlled trials (SPECTRA and VICI) with eplerenone did not demonstrate significant benefit, suggesting insufficient evidence for routine use, according to the American Academy of Ophthalmology 3

Critical Monitoring and Safety Considerations

• The European Society of Cardiology recommends checking renal function and serum electrolytes at baseline, 1 week, 4 weeks, then at 1, 2, 3, and 6 months, and every 6 months thereafter 1
• Hyperkalemia risk is significant, particularly in elderly patients, those with diabetes, kidney disorders, or liver disease, as noted by the American Heart Association 3
• If potassium rises to >5.5 mmol/L, the European Society of Cardiology recommends halving the dose (e.g., 25 mg on alternate days) 1
• If potassium rises to ≥6.0 mmol/L, the European Society of Cardiology recommends stopping spironolactone immediately and monitoring closely; specific treatment may be needed 1
• If creatinine rises to >220 μmol/L (2.5 mg/dL), the European Society of Cardiology recommends halving the dose 1
• If creatinine rises to >310 μmol/L (3.5 mg/dL), the European Society of Cardiology recommends stopping spironolactone immediately 1
• Hepatic encephalopathy occurs in up to 25% of hospitalized patients on diuretics, according to the European Association for the Study of the Liver 2
• Renal impairment occurs in 14-20%, especially without peripheral edema, but is usually reversible, as noted by the European Association for the Study of the Liver 2
• Hyponatremia occurs in 8-30%, according to the European Association for the Study of the Liver 2
• Adverse event prevalence ranges from 19-33%, with almost half requiring dose reduction or discontinuation, as reported by the European Association for the Study of the Liver 2
• Gynecomastia and decreased libido in men (10% in RALES trial) are common side effects, according to the European Society of Cardiology 1

Spironolactone's Clinical Applications and Pharmacological Effects

Mechanism of Action and Pharmacokinetics

• The drug slows the exchange of sodium and potassium in the distal tubule by competing with aldosterone for binding sites, leading to increased natriuresis while conserving potassium, as observed in patients with hepatic cirrhosis with ascites 4
• There is a lag of 3-5 days between the beginning of spironolactone treatment and the onset of the full natriuretic effect, which is important to consider when initiating therapy in patients with conditions associated with secondary hyperaldosteronism 4

Clinical Applications and Efficacy

• In liver cirrhosis, spironolactone is considered the drug of choice for initial treatment of ascites, typically starting at 100 mg/day and potentially increasing up to 400 mg/day to achieve adequate natriuresis, as recommended by clinical guidelines 4
• Spironolactone appears effective for hypertension management at doses of 25-100 mg/day, although the optimal dosage may vary depending on individual patient response 4

Side Effects and Monitoring

• Common side effects of spironolactone include headache, diarrhea, fatigue, gynecomastia, decreased libido, and menstrual disruption, occurring in more than 10% of patients, according to the American Heart Association 5
• Hyperkalemia is a significant potential complication that requires monitoring, especially in patients with diabetes mellitus, liver disorders, kidney disorders, and elderly patients, as emphasized by the European Society of Cardiology 5
• Contraindications include concomitant use of potassium supplements, other potassium-sparing diuretics, potent CYP3A4 inhibitors, and combined use of an angiotensin-converting enzyme inhibitor with an angiotensin receptor blocker, as stated by the American College of Cardiology 5
• The use of spironolactone is also contraindicated with certain medications, including potassium supplements, other potassium-sparing diuretics, and potent CYP3A4 inhibitors, due to the increased risk of hyperkalemia, as warned by the National Institute of Health 6

Comparison to Other Mineralocorticoid Receptor Antagonists

• Spironolactone is currently considered the most potent mineralocorticoid receptor antagonist used in clinical practice, making it particularly effective despite its side effect profile, according to the European Society of Hypertension 6
• Spironolactone has demonstrated beneficial effects in central serous chorioretinopathy (CSC), including improved best-corrected visual acuity, reduced choroidal thickness, and reduced subretinal fluid, as reported by the American Academy of Ophthalmology 6

Spironolactone Discontinuation in Decompensated Liver Disease

Key Reasons for Discontinuation in Decompensated Cirrhosis

• The European Association for the Study of the Liver (EASL) guidelines recommend reducing or discontinuing spironolactone in patients with decompensated cirrhosis and refractory ascites when systolic blood pressure is less than 90 mmHg, indicating severe circulatory dysfunction 7
• The EASL guidelines also suggest reassessing therapy in patients with serum creatinine greater than 1.5 mg/dL, indicating vulnerable renal function 7
• Patients with serum sodium less than 130 mmol/L are at increased risk of severe circulatory dysfunction, according to the EASL guidelines 7

Distinguishing Cardiac vs. Hepatic Indications

• When heart failure and decompensated cirrhosis coexist, the European Society of Cardiology recommends continuing mineralocorticoid receptor antagonists (MRAs) like spironolactone in acute decompensated heart failure with low blood pressure, as they have minimal impact on blood pressure compared to other guideline-directed therapies 8, 9
• Discontinuing spironolactone in heart failure is associated with a 2-4 fold higher risk of subsequent adverse cardiovascular events, according to the European Society of Cardiology 8, 9

Spironolactone's Impact on Alkalosis

Mechanism and Clinical Context

• The American Heart Association recommends that spironolactone be used with caution in patients with heart failure, as it can worsen metabolic alkalosis in the short term, but is essential for treating the underlying causes of alkalosis, with a mortality benefit of 30% in severe heart failure 10, 11
• The European Association for the Study of the Liver suggests that spironolactone achieves 95% response rates for ascites control in cirrhosis, versus 52% for furosemide alone, making it first-line therapy despite alkalosis risk 12
• The American Academy of Pediatrics recommends that spironolactone be used with caution in pediatric patients with chronic lung disease, as it can prevent hypokalemia-induced alkalosis and CO2 retention, with adequate KCl supplementation and periodic monitoring of serum electrolytes 13

Management and Monitoring

• The American College of Cardiology recommends that patients with mild alkalosis (pH 7.45-7.50, HCO3 30-35 mEq/L) continue spironolactone with close monitoring, while those with moderate-severe alkalosis (pH >7.50, HCO3 >35 mEq/L) require adjunctive therapy 10, 11
• The National Institute of Diabetes and Digestive and Kidney Diseases suggests that patients with spironolactone-induced alkalosis require monitoring of electrolytes, renal function, and arterial blood gas at regular intervals, with more frequent monitoring if alkalosis develops or if loop diuretic doses are increased 11, 14

Special Populations

• The Heart Failure Society of America recommends that spironolactone be continued even in acute decompensated heart failure with low blood pressure, as it has minimal impact on blood pressure compared to other therapies, with a 2-4 fold increase in adverse cardiovascular events if discontinued 10, 11
• The American Association for the Study of Liver Diseases suggests that spironolactone be started at 100 mg daily and increased to 400 mg if needed, before adding furosemide, in patients with cirrhosis and ascites, with careful monitoring of systolic BP, creatinine, and sodium levels 10, 12